. . . "Hor\u00E1kov\u00E1, Dagmar" . "Z\u00E1n\u011Bt jako rizikov\u00FD faktor rozvoje inzul\u00EDnov\u00E9 rezistence"@cs . "57" . "[9AC9A276867E]" . "RIV/61989592:15110/12:33139833!RIV13-MZ0-15110___" . . . . "15110" . . "4"^^ . . . . "Inflammation as a Risk Factor for the Development of Insulin Resistance"@en . "C-reactive protein (CRP) is a sensitive marker of inflammation. It has been shown to be potentially useful as an indicator for predicting the risk of metabolic syndrome, based on the development of insulin resistance. The study verified CRP levels in selected groups of individuals and their correlations with parameters typical for insulin resistance. The following groups were studied: healthy individuals (A, n=126), obese individuals (B, n=213) and patients diagnosed with metabolic syndrome (C, n=79). Obese persons in Group B had parameters suggestive of early insulin resistance: hypertension, hyperglycaemia, QUICKI (0.305), lower adiponectin and higher aFABP levels as compared with the healthy subjects. Group C individuals were diagnosed with metabolic syndrome, as evidenced by the QUICKI markers for insulin resistance (0.293), much lower adiponectin (7.3 mg/L) and high aFABP levels (35.3 mg/L). CRP concentrations were lowest in Group A healthy individuals (0.75 mg/L), higher in Group B obese subjects (2.65 mg/L) and highest in Group C patients with metabolic syndrome (3.62 mg/L). The highest correlations were between CRP and aFABP (0.46) and between aFABP and Body Mass Index (0.57). The pathophysiology of insulin resistance is contributed to by subclinical inflammatory reaction, mainly expressed in visceral adipose tissue. Obese individuals were found to have CRP concentrations different from those in healthy individuals, approaching the level of 3 mg/L, known as the risk level. Individuals with metabolic syndrome had risk CRP levels. The presence of obesity in association with increased CRP levels is considered a significant predictor of the gradual development of metabolic syndrome."@en . "C-reaktivn\u00ED protein (CRP) je citliv\u00FD marker z\u00E1n\u011Btu, jeho\u017E hladiny se zvy\u0161uj\u00ED u jedinc\u016F s diabetem a metabolick\u00FDm syndromem v souvislosti s rozvojem subklinick\u00E9ho z\u00E1n\u011Btu. Ukazuj\u00ED se mo\u017Enosti vyu\u017Eit\u00ED stanoven\u00ED hladin CRP jako indik\u00E1toru potenci\u00E1ln\u00EDho rizika onemocn\u011Bn\u00ED metabolick\u00FDm syndromem nebo ateroskler\u00F3zou na podklad\u011B rozvoje inzul\u00EDnov\u00E9 rezistence. Pr\u00E1ce ov\u011B\u0159uje koncentrace C-reaktivn\u00EDho proteinu u vybran\u00FDch skupin jedinc\u016F a jejich korelace s parametry typick\u00FDmi pro inzul\u00EDnovou rezistenci. Byly studov\u00E1ny skupiny zdrav\u00FDch jedinc\u016F (A, n=126), jedinc\u016F s obezitou (B, n=213) a jedinc\u016F s diagn\u00F3zou metabolick\u00E9ho syndromu (C, n=79). Jedinci s obezitou ve skupin\u011B B maj\u00ED parametry sv\u011Bd\u010D\u00EDc\u00ED pro po\u010D\u00EDnaj\u00EDc\u00ED inzul\u00EDnovou rezistenci: hypertenzi, hyperglykemii, QUICKI (0,305), ni\u017E\u0161\u00ED adiponektinemii a vy\u0161\u0161\u00ED aFABP ve srovn\u00E1n\u00ED se skupinou zdrav\u00FDch. Jedinci ve skupin\u011B C maj\u00ED diagn\u00F3zu metabolick\u00E9ho syndromu, \u010Demu\u017E odpov\u00EDdaj\u00ED markery inzul\u00EDnov\u00E9 rezistence QUICKI (0,293), v\u00EDce se sni\u017Euj\u00EDc\u00ED adiponektinemie (7,3 mg/l) a vysok\u00E9 aFABP (35,3 mg/l). Koncentrace CRP je ve skupin\u011B zdrav\u00FDch A nejni\u017E\u0161\u00ED (0,75 mg/l), ve skupin\u011B ob\u00E9zn\u00EDch B se zvy\u0161uje (2,65 mg/l) a ve skupin\u011B C s metabolick\u00FDm syndromem je nejvy\u0161\u0161\u00ED (3,62 mg/l). Nejv\u011Bt\u0161\u00ED korelace je mezi CRP a aFABP (0,46) a d\u00E1le pak mezi aFABP a Body Mass Index (BMI) (0,57). Na patofyziologii rozvoje inzul\u00EDnov\u00E9 rezistence se pod\u00EDl\u00ED subklinick\u00E1 z\u00E1n\u011Btliv\u00E1 reakce, vyj\u00E1d\u0159en\u00E1 hlavn\u011B ve viscer\u00E1ln\u00ED tukov\u00E9 tk\u00E1ni. U ob\u00E9zn\u00EDch jedinc\u016F byly stanoveny koncentrace CRP odli\u0161n\u00E9 od zdrav\u00FDch jedinc\u016F, kter\u00E9 se p\u0159ibli\u017Euj\u00ED k hladin\u011B 3 mg/l ozna\u010Dovan\u00E9 za rizikovou. Jedinci s metabolick\u00FDm syndromem vykazovali hodnoty CRP rizikov\u00E9. P\u0159\u00EDtomnost obezity v asociaci se zv\u00FD\u0161en\u00EDm hladiny CRP je pova\u017Eov\u00E1no za v\u00FDznamn\u00FD rizikov\u00FD faktor postupn\u00E9ho rozvoje metabolick\u00E9ho syndromu."@cs . . "Koll\u00E1rov\u00E1, Helena" . . "C-reaktivn\u00ED protein (CRP) je citliv\u00FD marker z\u00E1n\u011Btu, jeho\u017E hladiny se zvy\u0161uj\u00ED u jedinc\u016F s diabetem a metabolick\u00FDm syndromem v souvislosti s rozvojem subklinick\u00E9ho z\u00E1n\u011Btu. Ukazuj\u00ED se mo\u017Enosti vyu\u017Eit\u00ED stanoven\u00ED hladin CRP jako indik\u00E1toru potenci\u00E1ln\u00EDho rizika onemocn\u011Bn\u00ED metabolick\u00FDm syndromem nebo ateroskler\u00F3zou na podklad\u011B rozvoje inzul\u00EDnov\u00E9 rezistence. Pr\u00E1ce ov\u011B\u0159uje koncentrace C-reaktivn\u00EDho proteinu u vybran\u00FDch skupin jedinc\u016F a jejich korelace s parametry typick\u00FDmi pro inzul\u00EDnovou rezistenci. Byly studov\u00E1ny skupiny zdrav\u00FDch jedinc\u016F (A, n=126), jedinc\u016F s obezitou (B, n=213) a jedinc\u016F s diagn\u00F3zou metabolick\u00E9ho syndromu (C, n=79). Jedinci s obezitou ve skupin\u011B B maj\u00ED parametry sv\u011Bd\u010D\u00EDc\u00ED pro po\u010D\u00EDnaj\u00EDc\u00ED inzul\u00EDnovou rezistenci: hypertenzi, hyperglykemii, QUICKI (0,305), ni\u017E\u0161\u00ED adiponektinemii a vy\u0161\u0161\u00ED aFABP ve srovn\u00E1n\u00ED se skupinou zdrav\u00FDch. Jedinci ve skupin\u011B C maj\u00ED diagn\u00F3zu metabolick\u00E9ho syndromu, \u010Demu\u017E odpov\u00EDdaj\u00ED markery inzul\u00EDnov\u00E9 rezistence QUICKI (0,293), v\u00EDce se sni\u017Euj\u00EDc\u00ED adiponektinemie (7,3 mg/l) a vysok\u00E9 aFABP (35,3 mg/l). Koncentrace CRP je ve skupin\u011B zdrav\u00FDch A nejni\u017E\u0161\u00ED (0,75 mg/l), ve skupin\u011B ob\u00E9zn\u00EDch B se zvy\u0161uje (2,65 mg/l) a ve skupin\u011B C s metabolick\u00FDm syndromem je nejvy\u0161\u0161\u00ED (3,62 mg/l). Nejv\u011Bt\u0161\u00ED korelace je mezi CRP a aFABP (0,46) a d\u00E1le pak mezi aFABP a Body Mass Index (BMI) (0,57). Na patofyziologii rozvoje inzul\u00EDnov\u00E9 rezistence se pod\u00EDl\u00ED subklinick\u00E1 z\u00E1n\u011Btliv\u00E1 reakce, vyj\u00E1d\u0159en\u00E1 hlavn\u011B ve viscer\u00E1ln\u00ED tukov\u00E9 tk\u00E1ni. U ob\u00E9zn\u00EDch jedinc\u016F byly stanoveny koncentrace CRP odli\u0161n\u00E9 od zdrav\u00FDch jedinc\u016F, kter\u00E9 se p\u0159ibli\u017Euj\u00ED k hladin\u011B 3 mg/l ozna\u010Dovan\u00E9 za rizikovou. Jedinci s metabolick\u00FDm syndromem vykazovali hodnoty CRP rizikov\u00E9. P\u0159\u00EDtomnost obezity v asociaci se zv\u00FD\u0161en\u00EDm hladiny CRP je pova\u017Eov\u00E1no za v\u00FDznamn\u00FD rizikov\u00FD faktor postupn\u00E9ho rozvoje metabolick\u00E9ho syndromu." . "P(NT11098)" . . . "Z\u00E1n\u011Bt jako rizikov\u00FD faktor rozvoje inzul\u00EDnov\u00E9 rezistence"@cs . "181614" . . "Z\u00E1n\u011Bt jako rizikov\u00FD faktor rozvoje inzul\u00EDnov\u00E9 rezistence" . "1802-6281" . "4"^^ . "Z\u00E1n\u011Bt jako rizikov\u00FD faktor rozvoje inzul\u00EDnov\u00E9 rezistence" . "Inflammation as a Risk Factor for the Development of Insulin Resistance"@en . "4"^^ . . . "Janout, Vladim\u00EDr" . . . "2" . "Hygiena : \u010Dasopis pro ochranu a podporu zdrav\u00ED" . "CZ - \u010Cesk\u00E1 republika" . "RIV/61989592:15110/12:33139833" . . "disease prevention; obesity; metabolic syndrome prevention; diabetes mellitus prevention"@en . "Azeem, Kate\u0159ina" .